Cellyan CFO Liu Shu files initial Form 3

Cellyan Biotechnology Co., Ltd filed an initial Form 3 for CFO Liu Shu.

Rhea-AI Filing Summary

Cellyan Biotechnology Co., Ltd filed an initial Form 3 for CFO Liu Shu. This filing identifies Liu Shu as an officer of the company but does not report any buy, sell, or other insider transactions, and shows no derivative positions or holding entries at this time.

Key Figures

Buy transactions: 0 Sell transactions: 0 Derivative transactions: 0

3 metrics

Buy transactions 0 BuyCount in transaction summary

Sell transactions 0 SellCount in transaction summary

Derivative transactions 0 derivativeTransactionCount in transaction summary

Key Terms

Form 3, reportingPersons, derivativeSummary, netBuySellDirection

4 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3): {"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reportingPersons regulatory

""reportingPersons": [ { "name": "Liu Shu""

derivativeSummary financial

""derivativeSummary": [],"

netBuySellDirection financial

""netBuySellDirection": "neutral""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Cellyan Biotechnology (HKPD) disclose in this Form 3?

The Form 3 identifies Liu Shu as the CFO and a reporting person of Cellyan Biotechnology Co., Ltd. It is an initial statement and shows no insider transactions or derivative positions in this filing.

Does Liu Shu report any stock transactions in Cellyan Biotechnology (HKPD) Form 3?

No transactions are reported. The transaction summary shows zero buys, zero sells, and no other transaction types. This Form 3 mainly serves to register Liu Shu as a reporting person for future ownership disclosures.

Are there any derivative securities reported for Liu Shu in HKPD’s Form 3?

No derivative securities are reported. The derivativeSummary is empty and derivativeTransactionCount is 0, indicating no options, warrants, or similar instruments are disclosed in this initial statement.

What does the transaction summary in Cellyan Biotechnology (HKPD) Form 3 show?

The transaction summary lists 0 buys, 0 sells, 0 exercises, 0 gifts, and netBuySellDirection as neutral. It indicates there were no insider trading activities reported in this filing for Liu Shu.

Does this Cellyan Biotechnology (HKPD) Form 3 include any tax withholding or restructuring events?

No. The summary shows taxWithholdingCount 0 and restructuringCount 0, meaning there are no tax-withholding dispositions or restructuring-related ownership changes reported for Liu Shu in this initial filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 02:25 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Liu Shu

(Last) (First) (Middle)

ROOM 5102, INTERNATIONAL

ARBITRATION BUILDING NANSHAN DISTRICT

(Street)

SHENZHEN CITY GUANGDONG PROVINCE 518052

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Cellyan Biotechnology Co., Ltd [ HKPD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Shu Liu	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)